Welcome to the ICD-10 code for sarcopenia

This is the editorial by Anker, Morley, and von Haehling in the Journal of Cachexia, Sarcopenia and Muscle marking the assignment of ICD-10-CM code M62.84 to sarcopenia. The piece is short (three pages) and structurally a commentary rather than a primary research paper, but its load-bearing role in the sarcopenia-and-peptides conversation is the institutional reframing it documents. Sarcopenia received its own ICD-10-CM code on 1 October 2016, an administrative event that the editorial situates within a longer arc — from Rosenberg's 1989 coinage of the term, through the EWGSOP 2010 first-iteration consensus definition, to the international working groups that drove the coding submission to the National Center for Health Statistics.

The editorial's significance is the institutional separation it formalizes. Prior to the ICD-10-CM assignment, sarcopenia in clinical billing and registry contexts was coded under broad categories — "abnormality of gait and mobility," "muscular atrophy not elsewhere classified," "general age-related decline" — that conflated sarcopenia with cachexia, with disuse atrophy, and with frailty-as-syndrome. M62.84 separates sarcopenia operationally from those overlapping but mechanistically distinct conditions. Cachexia (the catabolic muscle loss of cancer, advanced heart failure, severe COPD) is coded separately under R64; disuse atrophy under M62.5; inflammatory myopathy under the M60 family; frailty under R54. The clean separation matters for trial-population definition (a sarcopenia trial enrolling under M62.84 is a different population than a cachexia trial), for epidemiological surveillance (prevalence estimates can be derived from health-system data rather than only from research cohorts), and for the pharmaceutical-development pathway (regulatory submissions targeting sarcopenia as indication can now be assessed against a defined patient population rather than against a non-coded clinical syndrome).

The editorial briefly surveys the contemporary treatment options. Resistance exercise is described as universally effective with effect sizes demonstrated even in the very old. Leucine-enriched amino acid supplementation, vitamin D status optimization, and adequate protein intake compose the nutritional floor. Pharmacologically, the authors flag testosterone, anamorelin, and emerging myostatin inhibitors as the candidate pharmacological adjuncts being developed. The framing of anamorelin is forward-looking — at the editorial's publication in late 2016, Temel et al. had just reported the ROMANA-1 and ROMANA-2 Phase 3 results (Temel et al. 2016) showing lean-mass gain without handgrip-strength improvement in NSCLC cachexia, and Japan's PMDA approval was still four years out. The editorial does not pre-judge the EMA rejection that would follow in 2017 or the Japanese PMDA approval that would follow in 2020 (Wakabayashi, Arai, Inui 2021).

The structural editorial point — the institutional separation of sarcopenia from neighboring conditions — is where the piece earns its place in the sarcopenia-and-peptides dossier. The cachexia-versus-sarcopenia distinction is what allows the dossier to separate the cachexia-trial evidence (Temel et al. 2016 on anamorelin in advanced cancer) from the sarcopenia-relevant evidence (Nass et al. 2008, Adunsky et al. 2011 in older adults) without treating them as part of the same indication. The shared GHSR-1a-agonist mechanism allows class-level inferences; the population distinction prevents conflation of treatment effects. M62.84 is the administrative anchor under that distinction.